5ALPHA-REDUCTASE INHIBITORS FOR REDUCT OF PROSTATE EPITHELIAL CELL GROWTH
5 种用于减少前列腺上皮细胞生长的α-还原酶抑制剂
基本信息
- 批准号:8360341
- 负责人:
- 金额:$ 8.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AmericanAndrogensAutomobile DrivingBenign Prostatic HypertrophyBotanicalsCell ProliferationChibro-ProscarDevelopmentDiagnosisDiseaseDutasterideEffectivenessEnzymesEpithelialEpithelial CellsFinasterideFundingGlaxoSmithKline brand of dutasterideGrantGrowthHealthMalignant NeoplasmsMalignant neoplasm of prostateNational Center for Research ResourcesNutrientOxidoreductasePrincipal InvestigatorProstatePublic HealthReportingResearchResearch InfrastructureResourcesSabal serrulataSalesSaw palmetto extractSourceStanoloneTestosteroneTherapeuticUnited States National Institutes of Healthcell growthcombatcostimplantationinhibitor/antagonistmalementumor
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Prostate cancer is the most commonly diagnosed male cancer. Thus, preventative and/or therapeutic strategies to combat this cancer could have a profound impact on public health. The 5¿-reductase inhibitors finasteride (Proscar¿) and dutasteride (Avodart¿) are commonly used to treat benign prostatic hyperplasia (BPH), but may also potentially decrease the development and/or progression of prostate cancer. 5¿-reductase enzymes convert testosterone to the more potent androgen dihydrotestosterone, which is important for driving the growth of most prostate cancers. Specific Aim 1 will examine the effectiveness of finasteride and dutasteride when begun before or after tumor implantation. Saw palmetto extracts have also been used to treat BPH and are reported to decrease 5¿-reductase enzymes, but there has been a lot of inconsistency their reported effectiveness. Despite the saw palmetto's questionable effectiveness, it is commonly used by Americans, ranking in the top 5 of botanical sales and is commonly used by men with prostate cancer. We believe that the variable results between studies may be due to differences in the extracts nutrient profiles, which have been reported to vary widely. Specific Aim 2 we will collect commonly used commercial saw palmetto extracts and characterize their nutrient profiles. We will then determine whether an extract's nutrient profile correspond to its ability to inhibit 5¿-reductase and cell proliferation of prostate cancer epithelial cells.
该副本是利用资源的众多研究子项目之一
由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持
而且,副投影的主要研究员可能是其他来源提供的
包括其他NIH来源。列出的总费用可能
代表subproject使用的中心基础架构的估计量,
NCRR赠款不直接向子弹或副本人员提供的直接资金。
前列腺癌是最常见的男性癌症。这是对抗这种癌症的预防和/或治疗策略,可能会对公共卫生产生深远的影响。通常使用5届还原酶抑制剂抑制剂(Proscar�)和Dutakeride(Avodart?)来治疗良性的前列腺增生(BPH),但也可能会降低前列腺癌的发展和/或进展。 5�-还原酶将睾丸激素转化为较大的雄激素二氢睾丸激素,这对于推动大多数前列腺癌的生长很重要。特定的目标1将在肿瘤植入后或之后检查非那雄胺和Dutasteride的有效性。 SAW Palmetto提取物也已用于治疗BPH,据报道可降低5—还原酶,但其报道的有效性很大。尽管Saw Palmetto具有可疑的有效性,但美国人通常使用它,在植物销售的前五名中排名,前列腺癌男性通常使用。我们认为,研究之间的可变结果可能是由于提取物养分谱的差异所致,据报道,这些谱图差异很大。具体目的2我们将收集常用的商业锯棕榈提取物,并表征其营养谱。然后,我们将确定提取物的养分特征是否对应于其抑制5-还原酶和前列腺癌上皮细胞的细胞增殖的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRIAN L LINDSHIELD其他文献
BRIAN L LINDSHIELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRIAN L LINDSHIELD', 18)}}的其他基金
5ALPHA-REDUCTASE INHIBITORS FOR REDUCTION OF PROSTATE EPITHELIAL CELL GROWTH
5 种减少前列腺上皮细胞生长的α-还原酶抑制剂
- 批准号:
8167834 - 财政年份:2010
- 资助金额:
$ 8.46万 - 项目类别:
相似国自然基金
雄激素通过免疫因子调控鹿茸再生的研究
- 批准号:32370899
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
当归多糖微针介导毛囊靶向递送巨噬细胞仿胞外囊泡治疗雄激素性脱发研究
- 批准号:82304732
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
甘氨脱氧胆酸通过FXR-FABP6促进雄激素转化代谢而改善PCOS的分子机制研究
- 批准号:82371643
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
黄芩苷抑制AR核转位在抗雄激素源性脱发中的作用及机制研究
- 批准号:82304649
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
DPP4通过GPx4和15-LOX双信号途径诱导毛乳头细胞铁死亡在雄激素性秃发毛囊微型化中的作用及机制
- 批准号:82304058
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Creating diverse communities in support of diabetes and metabolism research
创建多元化社区以支持糖尿病和代谢研究
- 批准号:
10794432 - 财政年份:2023
- 资助金额:
$ 8.46万 - 项目类别:
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
用协同治疗剂针对代谢脆弱性治疗转移性去势抵抗性前列腺癌。
- 批准号:
10677412 - 财政年份:2023
- 资助金额:
$ 8.46万 - 项目类别:
Adaptive resistance to AR inhibitors in hypoxia by GPT1
GPT1对缺氧环境下AR抑制剂的适应性抵抗
- 批准号:
10638774 - 财政年份:2023
- 资助金额:
$ 8.46万 - 项目类别:
Elucidating Synergy of Enzalutamide and Src Kinase Inhibitors in Castration-Resistant Prostate Cancer
阐明恩杂鲁胺和 Src 激酶抑制剂在去势抵抗性前列腺癌中的协同作用
- 批准号:
10476997 - 财政年份:2021
- 资助金额:
$ 8.46万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10450017 - 财政年份:2020
- 资助金额:
$ 8.46万 - 项目类别: